

conditions which allow the formation of an antibody-BoNT/A complex; and

(ii) detecting the antibody-BoNT/A complex wherein the presence or absence of the complex indicates the presence or absence of BoNT/A in the sample.

15 (Amended). The method for detecting BoNT/A according to claim 14 wherein, said monoclonal antibody is 6B2-2.

16 (Amended). The method for detecting BoNT/A according to claim 15 wherein, said sample is water, biological, pharmaceutical, or food products.

17 (Amended). A method of treating BoNT/A intoxication comprising administering to a patient in need of said treatment an amount of monoclonal antibody 6B2-2 sufficient to effect said treatment.

21 (Amended). A kit for detecting BoNT/A in a biological sample, said kit comprising:

(1) a container MAb 6B2-2; and

(2) instructions for using the antibody for the purpose of binding to BoNT/A to form an immunological complex and detecting the formation of the immunological complex such that presence or absence of immunological complex correlates with presence or absence of BoNT/A in said sample.

27 (Amended). A method for capturing BoNT/A from a sample, said method comprising contacting said sample with monoclonal antibody 6B2-2, and isolating the complex formed between the BoNT/A in the sample and the monoclonal antibody.